Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05927428 · ClinicalTrials.gov registry record · Phase 2
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
A Phase 2 study of Neurotrophic Keratitis, sponsored by BRIM Biotechnology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05927428 is a Phase 2 study of Neurotrophic Keratitis that is actively recruiting participants, run by BRIM Biotechnology. The registered enrollment target is 12 participants, below the 22-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05927428, a Phase 2 study of Neurotrophic Keratitis, is actively recruiting participants, sponsored by BRIM Biotechnology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Conditions Studied
Interventions
- DRUG BRM424 Ophthalmic Solution - Dose1
- DRUG BRM424 Ophthalmic Solution - Dose2
Study Locations (1)
North Carolina
- Wilmington Eye - Leland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05927428
The ClinicalTrials.gov registry entry for NCT05927428 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 22-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (45% lower). The listed sponsor is BRIM Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurotrophic Keratitis appearing as the primary indexed condition, and to 2 interventions - of which BRM424 Ophthalmic Solution - Dose1 is the first listed.
NCT05927428 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05927428 about?
NCT05927428 is a clinical study titled "Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis". The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
What is the current status of trial NCT05927428?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-07-31. Estimated completion is 2025-11-30.
What conditions does trial NCT05927428 study?
This clinical trial studies the following conditions: Neurotrophic Keratitis.
What interventions are being tested in trial NCT05927428?
The interventions under investigation include: BRM424 Ophthalmic Solution - Dose1 (DRUG), BRM424 Ophthalmic Solution - Dose2 (DRUG).
Who is sponsoring clinical trial NCT05927428?
This trial is sponsored by BRIM Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05927428 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurotrophic Keratitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
RECRUITING · Phase 1
-
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
RECRUITING
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
-
Corneal Nerves After Treatment With Cenegermin
COMPLETED
-
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.